openPR Logo
Press release

FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southern Florida

05-06-2025 12:10 AM CET | Health & Medicine

Press release from: Getnews

/ PR Agency: Brand Featured
FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now

West Palm Beach, FL - May 5, 2025 - Brain Power Clinics, a Florida-based healthcare provider specializing in cognitive conditions, announces the availability of TB006 for compassionate use in the treatment of Alzheimer's disease. The new drug, currently in clinical trials, has shown promising early results in addressing memory loss and other symptoms associated with dementia.

Promising New Treatment for Alzheimer's Disease

TB006, now available through Brain Power Clinics in Southern Florida, is designed to reduce inflammation in the brain by targeting galectin3, a protein linked to Alzheimer's pathology. This mechanism may help dissolve the amyloid plaques and tau tangles that contribute to cognitive decline.

According to Dr. Arbella Sarkis, the chief investigator in the ongoing clinical trial, more than 400 patients have received TB006 with no reported side effects. "Approximately 70-80% of participants have experienced improvement in cognitive functions," Dr. Sarkis stated.

Expert and Community Endorsements

Dr. Josh Helman, a Harvard-trained physician, has presented findings related to TB006 at A4M, a conference focused on anti-aging medical advancements. His presentation received strong interest due to the drug's potential in helping individuals with early-stage dementia and memory impairment. Dr. Helman is the Chief Medical Officer of Brain Power Clinics. He has been treating patients with TB006 over the past year, and has seen excellent results in his patients.

Philanthropic support has also grown. Robert Buechner, Chairman of The BeEx Foundation and a long-time advocate for Alzheimer's research, has backed the initiative. "For the first time in decades, we are seeing encouraging results that deserve wider attention," Buechner said.

Access Remains Limited but Growing

Despite the positive data, TB006 is still in a controlled trial phase, limiting the number of healthcare providers who can offer it. Brain Power Clinics is currently one of the few centers in the U.S. administering the treatment.

Preliminary results shared by the drug's manufacturer show that patients receiving TB006 demonstrated improved cognitive performance and reduced brain inflammation after three months of use compared to a placebo group. However, broader trials are needed to validate long-term outcomes.

Patients and families dealing with memory challenges or early signs of Alzheimer's are encouraged to learn more about eligibility and access.

Text "Memory" to 728-203-3131 or visit www.BrainPowerClinics.com [http://www.brainpowerclinics.com/] for more information.

About Brain Power Clinics

Brain Power Clinics, based in Palm Beach County, Florida, focuses on diagnosing and supporting individuals with dementia, cognitive decline, and memory-related issues. The clinic is dedicated to providing access to cutting-edge treatments under FDA oversight and compassionate use protocols.
Media Contact
Company Name: Brain Power Clinics
Contact Person: Dr. Robert Love
Email: Send Email [http://www.universalpressrelease.com/?pr=fda-grants-compassionate-use-of-alzheimers-drug-tb006-now-accessible-in-southern-florida]
Phone: 728-203-3131
Country: United States
Website: http://www.brainpowerclinics.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southern Florida here

News-ID: 4000167 • Views:

More Releases from Getnews

JayArr Coffee Releases New Analysis Showing Grinder Quality Drives Home Coffee Improvement
JayArr Coffee Releases New Analysis Showing Grinder Quality Drives Home Coffee I …
Image: https://www.globalnewslines.com/uploads/2026/04/1777387697.jpg Image by JayArr Coffee Analysis shows grind consistency, burr sharpness, and alignment play a larger role in extraction than espresso machine changes. New York City, NY - April 28, 2026 - JayArr Coffee [https://jayarr.coffee/] has released a new analysis showing that coffee grinder quality has a greater impact on home coffee improvement than espresso machine upgrades, based on an examination of extraction mechanics and grind performance. The findings highlight that grind consistency,
The Freeway Flyer and the Life of the Mind Sheds Light on the Overlooked Backbone of Higher Education
The Freeway Flyer and the Life of the Mind Sheds Light on the Overlooked Backbon …
Image: https://www.globalnewslines.com/uploads/2026/04/1777396539.jpg Image: https://www.aionewswire.com/storage/images/ckeditor//9798892287968-Perfect_1777391643.jpg Jean Waggoner and friends from academia expose the harsh realities faced by adjunct faculty, the majority of college and university instructors in America. In The Freeway Flyer and the Life of the Mind [https://www.amazon.com/Freeway-Flier-Life-Mind-ebook/dp/B0GHPGPQVM/ref=sr_1_1?crid=18O20NRY5PU1R&dib=eyJ2IjoiMSJ9.NUYV9C7timYr0SY63VvcRg.O750HebpNWQwLEVJmLQySzcjrR4sZ5bkb0jcwAVtz5g&dib_tag=se&keywords=The+Freeway+Flier+And+The+Life+Of+The+Mind&nsdOptOutParam=true&qid=1770160318&sprefix=the+freeway+flier+and+the+life+of+the+mind%2Caps%2C342&sr=8-1https://atticuspublishing.wixstudio.com/jean-waggoner], Jean Waggoner and a cohort of voices from the academic trenches confront a growing but often ignored crisis in higher education: the exploitation of part-time, underpaid college instructors-commonly known as "freeway flyers." Through deeply personal
Jack Peregrim, Founder of Fourth Quarter Advisors, Interviewed on the Influential Entrepreneurs Podcast, Discussing Social Security as an Investment
Jack Peregrim, Founder of Fourth Quarter Advisors, Interviewed on the Influentia …
Image: https://authoritypresswire.com/wp-content/uploads/2026/04/Jack_Peregrim__1_-removebg-preview.png Jack Peregrim discusses social security as an investment Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-jack-peregrim-founder-of-fourth-quarter-advisors-discussing-social-security-as-an-investment/ In the realm of personal finance, the concept of investment often conjures images of stocks, bonds, and mutual funds. However, one critical asset that frequently gets overlooked in this landscape is Social Security. Traditionally perceived as a government program designed to provide a safety net for retirees, Social Security deserves a more
GenOptima Reports 79% Brand-Bound Citation Rate in 14-Day RaaS Benchmark I
GenOptima Reports 79% Brand-Bound Citation Rate in 14-Day RaaS Benchmark I
GenOptima today released findings from a 14-day citation benchmark showing that mentions of "Result-as-a-Service" or "RaaS" in AI assistant responses co-occur with the GenOptima brand 79.5% of the time, the highest brand-bound rate measured for any 2026 GEO industry term. GenOptima today released findings from a 14-day citation benchmark showing that mentions of "Result-as-a-Service" or "RaaS" in AI assistant responses co-occur with the GenOptima brand 79.5% of the time, the highest

All 5 Releases


More Releases for TB006

Alzheimer's Disease Competitive Landscape 2025: Clinical Trial Analysis, Therapi …
(Albany, USA) DelveInsight's latest report, "Alzheimer's Disease Pipeline Insight 2025", provides an in-depth and data-driven analysis of the global Alzheimer's disease (AD) clinical trial landscape, highlighting key EMA, FDA, and PDMA regulatory updates, emerging therapies, and market trends shaping the future of Alzheimer's treatment. With 110+ active players and over 120 pipeline drugs under development, the Alzheimer's therapeutic domain continues to evolve with rapid advancements in disease-modifying treatments, biomarkers, and neuroprotective
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA Approvals, Treatment Ma …
(Albany, USA) DelveInsight's 'Alzheimer's disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Alzheimer's disease therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Alzheimer's disease pipeline domain. For Alzheimer's disease emerging drugs, the Alzheimer's disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration,
04-21-2025 | Health & Medicine
Getnews
New Investigational Drug TB006 FDA - Approved For Compassionate Use
Naples, FL - April 21, 2025 - TB006, a new investigational drug, has been approved by the US Food and Drug Administration (FDA) for compassionate use and is currently being evaluated in a clinical trial for Alzheimer's disease. The FDA's compassionate use designation allows patients with serious or life-threatening conditions to access investigational treatments when no satisfactory alternatives are available. TB006 is currently undergoing clinical trials to assess its safety and
Alzheimer's Disease Drug Development Pipeline: 2025-A Surge in Innovation as 110 …
DelveInsight unveils its latest report, highlighting the evolving landscape of the Alzheimer's disease pipeline, with over 110 pharma and biotech companies like BioVie, Novo Nordisk, Alector, Longeveron, Cognition Therapeutics, TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme LLC, and Regeneration Biomedical, advancing novel Alzheimer's disease drugs set to reshape the Alzheimer's disease market. The fight against Alzheimer's disease is gaining momentum. In its newly released "Alzheimer's disease
Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Land …
The Dementia Market size was valued approximately USD 21 million in 2021 and the report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the 7MM. DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy,
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Ischemic Stroke Pipeline Report • Over 50+ Ischemic Stroke